Seeking Alpha

FDA approves Novartis breakthrough therapy cancer drug

  • The FDA gives a thumbs up to Novartis' (NVS +1.2%) Zykadia (ceritinib) as a treatment for patients with a certain type of late-stage (metastatic) non-small cell lung cancer months ahead of schedule.
  • Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that blocks cancer cell-promoter proteins.
  • The agency granted Zykadia breakthrough therapy designation, priority review and orphan drug designation. Its clearance comes four months ahead of the August 24 PDUFA date.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|